E
GT Biopharma, Inc. GTBP
$2.29 -$0.04-1.72% NASDAQ
Recommendation
Prev Close
$2.33
Volume
2,558
Avg Vol (90D)
620,430
Market Cap
$5.91M
Dividend & Yield
--
52-Week Range
$1.72 - $10.66
P/E (TTM)
--
EPS (TTM)
-$7.01
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Drops By 23.2%
4/21/2025 - Ticker Report
Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Drops By 62.4%
3/28/2025 - Ticker Report
GT Biopharma files to sell 625,283 shares of common stock for holders
3/6/2025 - TipRanks Financial Blog
GT Biopharma files to sell 625,283 shares of common stock for holders
3/6/2025 - The Fly
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
3/4/2025 - GuruFocus
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
3/4/2025 - Globe Newswire
GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak
2/26/2025 - Stocktwits News Feed
GT Biopharma Announces Exercise of Warrants
2/25/2025 - GuruFocus
GT Biopharma Announces Exercise of Warrants
2/25/2025 - Globe Newswire
GT Biopharma could report Phase 1 trial data later this year, says Roth MKM
2/25/2025 - TipRanks Financial Blog
GT Biopharma could report Phase 1 trial data later this year, says Roth MKM
2/25/2025 - The Fly
GT Biopharma announces request for withdrawal of Form S-1 registration statement
2/25/2025 - The Fly
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement
2/25/2025 - GuruFocus
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement
2/25/2025 - Globe Newswire
First Patient Dosed in Phase 1 Trial of GTB-3650On January 27, 2025, GT Biopharma, Inc. (NASDAQ:GTBP) made a significant stride in its clinical development efforts with the announcement that the first patient was dosed in the Phase 1 Trial of GTB-365
1/28/2025 - Ticker Report
GT Biopharma announces first patient dosed in Phase 1 trial of GTB-3650
1/27/2025 - The Fly
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation ...
1/27/2025 - GuruFocus
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
1/27/2025 - Globe Newswire
Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Increases By 23.4%
12/31/2024 - Ticker Report
GT Biopharma files for automatic mixed securities shelf
12/23/2024 - SeekingAlpha.com: All News
GT Biopharma files automatic mixed securities shelf
12/23/2024 - The Fly
GT Biopharma (NASDAQ:GTBP) versus Allakos (NASDAQ:ALLK) Financial Analysis
12/17/2024 - Ticker Report
GT Biopharma (NASDAQ:GTBP) Upgraded at Roth Capital
12/5/2024 - Ticker Report
Roth Mkm Begins Coverage on GT Biopharma (NASDAQ:GTBP)
12/4/2024 - Ticker Report
GT Biopharma initiated with a Buy at Roth MKM
12/2/2024 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$14.36M
Net Income (TTM)
-$13.16M
Balance Sheet
Total Assets (Q)
$4.23M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$5.90M
Book Value Per Share (Q)
-$0.7479
Cash Flow
Cash from Operations (TTM)
-$12.90M
Cash from Investing (TTM)
$12.89M
Cash from Financing (TTM)
$2.98M
Net Change in Cash (TTM)
$2.97M
Filings
Filing Date
Friday, February 21, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
(est)
Price History
Loading...
Beta
0.87
7-Day Total Return
0.35%
30-Day Total Return
-8.40%
60-Day Total Return
4.57%
90-Day Total Return
31.23%
Year to Date Total Return
-22.11%
1-Year Total Return
-30.61%
2-Year Total Return
-74.38%
3-Year Total Return
-96.37%
5-Year Total Return
-96.67%
52-week Low
Dec 20, 2024 - $1.72
52-week High
May 20, 2024 - $10.66
Valuation
Market Cap
$5.91M - Nano Cap
Enterprise Value
$1.96M
Price/Sales (TTM)
--
Price/Book (Q)
-3.12
Dividends and Shares
Shares Outstanding
2.26M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.gtbiopharma.com
Phone Number
415 919 4040
Address
315 Montgomery Street
San Francisco, CA 94104
Country
United States
Year Founded
1965
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager... more
NASDAQ 05/05/2025 2:21PM Eastern Quotes delayed